Received Jun 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | X012268 | — |
No symptoms or side effects; HCP called to report an expired dose of VARIVAX was administered to a patient on 6/18/2025.; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 19-JAN-2023, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) with sterile diluent (MERCK STERILE DILUENT) administered for prophylaxis (strength, lot number, expiration date, route and anatomical site of administration were not provided). On 18-JUN-2025, the patient was vaccinated with a second expired dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) injection, 0.5 mL, lot #X012268 [which has been verified go be valid lot number for Varicella Virus Vaccine Live (Oka-Merck)], expiration date reported and upon internal validation establish as 30-APR-2025. The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT), lot #Y016370, expiration date: 13-MAY-2027 upon internal validation. Both were administered for prophylaxis (strength, route and anatomical site of administration were not provided). Expired dose supported by post expiry memo (Expired product administered). Despite multiple reiterations of the supported outcome, customer not comprehending outcome and hung up despite offer to look into further resources if unclear. No symptoms or side effects (No adverse event). No previous temperature excursion.
Sterile diluent; Diluent MRK